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Abstract
The synthesis of three novel families of pyrrolo[2,1-c][1,4]benzodiazepine-5-ones is described. 
The compounds were prepared according to a three-step sequence, involving an Ugi reaction, 
building of the pyrrolo nucleus and reduction-cyclisation to the corresponding diazepine. 
Depending on the amine employed in the synthesis of the Ugi adducts, different unsaturation 
degrees could be obtained in the pyrrolo ring (saturated or with endo or exo unsaturations), a 
key feature determining their biological activity, as it affected the affinity of the 
pyrrolobenzoadiazepines towards DNA and thus their cytotoxicity. This synthetic methodology 
represents a significant improvement with respect to those described in the literature so far, 
as it uses inexpensive and commercially-available starting materials without needing 
derivatization or the use of protecting groups.
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Pyrrolobenzodiazepines (PBDs) constitute an important class of compounds thoroughly 
studied due to their activity as antitumour antibiotics.1 The cytotoxicity displayed by these 
compounds is related to their ability to bind covalently to DNA.2 Indeed, these compounds 
have been demonstrated to bind to DNA’s minor groove.3 A key feature for this interaction 
with DNA, and thus the cytotoxicity of these compounds, is the presence of an imine carbon, 
or equivalent, at the C11 position. This importance is underscored by the negligible cytotoxicity 
of analogous compound lacking this imine function. This occurs for instance when the imine 
group is replaced by an amide, as in PBD dilactames, or by a secondary amine.4 Examples of 
naturally-occurring PBD compounds displaying intriguing pharmacological properties include 
anthramycin,5 chicamycin6 and tomaymycin,7 all of them featuring an imine carbon, or 
equivalent, at the C11 position (Figure 1). From the biological perspective it is interesting to 
remark that the unsaturation degree of the pyrrole core affects the affinity of these systems 
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towards DNA as well as their cytotoxicity, both in compounds presenting exo8 and endo9 
























Figure 1. Examples of naturally-occurring bioactive pyrrolobenzodiazepines.
Numerous methodologies have been developed to synthesize these compounds,10 
reflecting their interest. The commonest route starts with L-proline, which allows the 
introduction of the five-membered core. This route was used for the synthesis of DC-81, an 
antitumor antibiotic produced by Streptomyces species,11 following two different strategies: 
(1) the synthesis of the PBD dilactame as intermediate, followed by the reduction of the 
carboxylic group derived from proline,12 or (2) the formation of the PBD system in the last step, 



































Figure 2. Intermediates in the synthesis of DC-81 starting from L-proline (blue 
fragment) or L-glutamic acid (red fragment)
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Nevertheless, few results are found in the literature where the precursor of the pyrrole 
system is an acyclic compound. In these cases, all the fragments which lead to the PBD are 
linked before the pyrrolo and diazepine cores are obtained, with derivatives of L-glutamic acid 
as precursors of the pyrrolo system being usually employed. This is the case of the synthetic 
route starting from L-glutamic acid 5-methyl ester, where the pyrrolo nucleus is obtained in 
the last step, in a sequence with a low global yield (10%).14 In an effort to improve this yield, a 
methodology was described employing as a starting material the dithioester derived from L-
glutamic acid, an unstable compound. This strategy allowed the simultaneous building of the 
five- and seven-membered rings in the last step, increasing the global yield up to 33% (Figure 
2).15 The third alternative, the construction of the pyrrolo nucleus before the diazepine core, 
has also been described, but all the methodologies reported so far involve many steps, as well 
as using specific and usually non-commercial substrates and/or protecting groups, which 
makes them less appealing than the previous ones.16
Prompted by the antitumor activity displayed by these molecules and taking into 
consideration our previous work with different benzodiazepines,17 we envisaged the possibility 
of synthesizing various pyrrolo[2,1-c][1,4]benzodiazepine-5-ones following analogous 
methodologies, based on Ugi’s reaction. Employing this reaction provides a solution to some of 
the above-mentioned issues, as it permits the use of commercial reagents which do not need 
to be derivatized, performing the synthesis under mild conditions and without the use of 
protecting groups. The compatibility of the isocyanide group with a large number of functional 
groups allows the introduction of doubly functionalized fragments in the molecule, eventually 
leading to the desired compounds. Herein, we describe the synthesis of three families of 
pyrrolo[2,1-c][1,4]benzodiazepine-5-ones derivatives with different unsaturation patterns in 
the pyrrolo nucleus (Figure 3). The synthetic strategy involves a three-step sequence, namely, 
an Ugi reaction/pyrrolo synthesis/reduction-cyclization to the diazepines in which the different 
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unsaturation degrees on the pyrrolo nucleus is controlled by the nature of the amine and the 























Figure 3. Pyrrolo[2,1-c][1,4]benzodiazepine-5-ones synthesized in this work (R1: alkyl, Ar: aryl).
Results and discussion
The first step in the described synthesis was the Ugi reaction. Three doubly functionalized 
reagents, two common in all reactions, 2-nitrobenzoic acid derivatives 2 and arylglyoxals 3, and 
a different functionalized amine 1 depending on the desired unsaturation degree, namely, 3-
bromopropylamine (used as its bromide salt) 1a, propargylamine 1b or 1-amino-3-butyne 1c, 
were reacted with the isocyanide 4, allowing the assembly of all the atoms which became part 






















1b: Z= C CH











2a: R1= H, R2: H
2b: R1= H, R2: Cl





Scheme 1. Linking all the fragments through the Ugi reaction.
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Table 1.  Results for the Ugi reaction.
Entry 1 (Z) 2 (R1, R2) 3 (R3) 4 (R4) 5a (%)
1 1a (CH2CH2Br) 2a (H, H) 3b (CH3) 4a (cC6H11) 5b (70)
2 1a (CH2CH2Br) 2b (H, Cl) 3a (H) 4a (cC6H11) 5f (68)
3 1b (CΞCH) 2a (H, H) 3a (H) 4a (cC6H11) 5j (69)
4 1b (CΞCH) 2a (H, H) 3b (CH3) 4a (cC6H11) 5k (79)
5 1b (CΞCH) 2a (H, H) 3d (OCH3) 4a (cC6H11) 5l (47)
6 1b (CΞCH) 2a (H, H) 3a (H) 4b (tBu) 5m (53)
7 1b (CΞCH) 2b (H, Cl) 3a (H) 4a (cC6H11) 5n (72)
8 1b (CΞCH) 2c (Cl, H) 3d (H) 4a (cC6H11) 5o (70)
9 1c (CH2CΞCH) 2a (H, H) 3d (H) 4a (cC6H11) 5p (87)
10 1c (CH2CΞCH) 2a (H, H) 3d (H) 4b (tBu) 5q (82)
11 1c (CH2CΞCH) 2c (Cl, H) 3d (H) 4a (cC6H11) 5r (82)
a 5a, 5c-5e, 5g-5i Ugi adduct intermediates for the synthesis of 6a, 6c-6e, 6g-i were not isolated but used 
directly in the next step 
The results were similar regardless of the starting amine and the substitution of the 
other components. Interestingly, no spontaneous cyclization was observed upon the formation 
of Ugi adducts 5a-i, derived from 3-bromopropylamine 1a as it was described for the 3-
bromopropionic acid derivatives.17b
The second step in these syntheses was the construction of the pyrrolo core from the 
Ugi adducts, which underscores the importance of the functionalization in the Ugi reactants to 
carry out the post-condensation reactions towards the desired intermediates.
In order to obtain the pyrrolidines 6, Ugi adducts 5b and 5f were isolated, in 70 and 
80% yield respectively, (Table 1, entries 1 and 2) and treated with cesium carbonate (1.5 
equiv.), yielding the corresponding pyrrolidine almost quantitatively (93 and 94 % yield of 
isolated pure pyrrolidines 6b and 6f respectively). However, the overall yield was improved 
when the Ugi/cyclization was carried out in a single step, i. e., adding the cesium carbonate to 
the reaction mixture in the Ugi reaction (Table 2, entries 2 and 6). This is probably due to the 
loss of the Ugi adduct during the purification process. In this way, pyrrolidines 6a-i were 
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synthesized in a single step from the four reactants through an Ugi reaction, followed by a 























3a: R3 = H
3b: R3 = CH3
3c: R3 = Cl
3d: R3 = OCH3
2a: R1 = H, R2: H
2b: R1 = H, R2: Cl
2c: R1 = Cl, R2: H
4a: R4 = cC6H11
4b: R4 = tBu







Scheme 2. Synthesis of pyrrolidines 6a-i from 3-bromopropylamine.
Table 2. Results for the synthesis of pyrrolidines 6a-i in a single step.
Entry 2 (R1, R2) 3 (R3) 4 (R4) 6 (%)
1 2a (H, H) 3a (H) 4a (cC6H11) 6a (86)
2 2a (H, H) 3b (CH3) 4a (cC6H11) 6b (89)a
3 2a (H, H) 3c (Cl) 4a (cC6H11) 6c (81)
4 2a (H, H) 3a (H) 4b (tBu) 6d (80)
5 2a (H, H) 3a (H) 4c (nBu) 6e (87)
6 2b (H, Cl) 3a (H) 4a (cC6H11) 6f (84)a
7 2c (Cl, H) 3b (CH3) 4a (cC6H11) 6g (87)
8 2c (Cl, H) 3a (H) 4b (tBu) 6h (76)
9 2c (Cl, H) 3d (OCH3) 4a (cC6H11) 6i (86)
a The two-steps overall yield was 65% for 6b and 64% for 6f.
The synthesis of dihydropyrroles was carried out from the Ugi adducts derived from 
propargylamine 1b. Two different strategies were examined as shown in Scheme 3 and Table 
3: (a) addition of metal salts, which would favor the formation of a complex between the 
dicarbonyl system, the alkyne and the metal ion; coordination would make the alkyne an 
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electrophile and would increase the nucleophilicity of the enol (Scheme 4),18 and (b) addition 
of bases, which would favor the formation of the allene from the propargyl anion, hence 














































Scheme 3. Cyclization of Ugi adduct 5j derived from 3-propargylamine.
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Table 3. Conditions for the cyclization of Ugi adduct 5j derived from 3-propargylamine.
Productsa
Entry Reagent Equiv. Solvent t (h) T (oC)
7a 8 9 10
1 InCl3 0.05 Chloroform 24 60 74 - 26 -
2 AgClO4 0.05 Chloroform 24 60 87 - - 13
3 AgClO4 0.05 Toluene 24 110 100 - - -
4 tBuOK 2.5 THF 1 20 34 - - 66
5 tBuOK 1 THF 1 20 66 - - 34
6 Na2CO3 2 Acetonitrile 6 80 100 - - -
a Ratio obtained by 1H NMR spectroscopy.
Firstly, different reaction conditions were tried in the presence of In(III), a well-known 
Lewis acid,20 as its chloride salt. Although 3-pyrroline 7a was systematically obtained, it was 
not the only product. Unexpectedly, methyleneazetidinone 9 was also formed (Table 3, entry 
1). The mechanism that drives the formation of both compounds would be similar: In(III) would 
coordinate simultaneously to the 1,3-dicarbonyl system and the alkyne ( and -coordination, 
respectively) and then the enolate would attack the triple bond intramolecularly (Scheme 4). 
However, the formation of 7 is favored over that of 9, since the former takes place through a 
5-endo-dig attack and the latter through a 4-exo-dig one although, according to Baldwin’s 
rules,21 the 4-exo-dig attack is not favored.
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Scheme 4. Cyclization mechanism of Ugi adducts derived from 3-propargylamine promoted by 
InCl3.
Interestingly, when the reaction was conducted in boiling chloroform in the presence 
of silver(I) perchlorate instead of indium(III) chloride, only the 5-endo-dig cyclization occurred; 
however, the debenzoylated product 10 was obtained together with the desired 3-pyrroline 7a 
(Table 3, entry 2). In order to avoid the formation of the former, the reaction was performed in 
boiling toluene, a solvent with lower water content than chloroform; in this way, 3-pyrroline 
7a was obtained exclusively (Table 3, entry 3).
To address the cyclization reaction from a second perspective, i. e., the addition of 
bases, potassium tert-butoxide and sodium carbonate were tried. The former is a common 
reagent for the formation of allenes from propargyl systems so, initially, 2.5 equiv. of 
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potassium tert-butoxide were added to a solution of 5j in THF and the reaction was carried out 
at room temperature. Although 2,3-dihydropyrrole 8 would be the expected product,22 a 
mixture of 7a and 10 was obtained, the latter being the major one (Table 3, entry 4). In view of 
this, the amount of base was reduced to one equivalent while keeping the remaining 
conditions (Table 3, entry 5), resulting in that, although 7a became the major product, the 


















































































Scheme 5. Proposed mechanism for the formation of 3-pyrrolines 7a and 10 promoted by 
bases 
In an attempt to explain the formation of the 3-pyrroline 7a instead of the expected 2-
pyrroline 8,22 Vazquez and colleagues have proposed a mechanism for an analogous system 
according to which the enolate would attack the alkyne’s terminal carbon.23 However, the 
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base-induced isomerization of propargyl amides to allenamides is well documented24 and, 
moreover, it is favoured in our reaction conditions (Table 3, entries 4 and 5).25 In this way, a 
plausible mechanism would start with the isomerization to the allenamide (A), which would 
undergo an intramolecular attack on the terminal carbon from the enolate (5-endo-trig 
cyclization), thus giving rise to vinyl carbanion B. The translocation of the allyl proton would 
originate an allyl anion (C), thus accounting for the isomerization of the double bond.26 The 
protonation of C would lead to 3-pyrroline 7a since they are more stable than 2-pyrrolines.27 
The retro-Claisen reaction on this 3-pyrroline 7a would yield the debenzoylated 3-pyrroline 10 
(Scheme 5).
With the aim of avoiding the debenzoylation reaction, the less nucleophilic sodium 
carbonate was employed as the base. Sodium carbonate is also less basic, so the temperature 
was increased. Typically, this kind of bases requires the use of boiling DMF,28 or of THF 
combined with a microwave oven,29 but surprisingly the reaction leading to 3-pyrroline 7a was 
quantitative in boiling acetonitrile (Table 3, entry 6). This approach is also safer and more 
ecofriendly than the use of silver(I) perchlorate. Therefore, a series of 3-pyrrolines was 























Scheme 6. Synthesis of 3-pyrrolines 7a-f from Ugi adducts 5j-o.
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Table 4. Global yields for the synthesis of 3-pyrrolines 7a-f from Ugi adducts 5j-o.
Entry 5 (R1, R2, R3, R4) 7 (%)
1 5j (H, H, H, cC6H11) 7a (81)
2 5k (H, H, CH3, cC6H11) 7b (73)
3 5l (H, H, OCH3, cC6H11) 7c (82)
4 5m (H, H, H, tBu) 7d (72)
5 5n (H, Cl, H, cC6H11) 7e (77)
6 5o (Cl, H, H, cC6H11) 7f (87)
Finally, the syntheses of the pyrrolidines incorporating an exo unsaturation in the 
pyrrolo core were conducted from Ugi adducts 5p-r derived from 1-amino-3-butyne 1c. 
Although the Ugi adducts were initially subjected to a basic treatment, employing both sodium 
carbonate and sodium tert-butoxide, in order to obtain the desired 3-methylenepyrrolidines, 
these trials were unsuccessful and the starting materials were recovered. The formation of the 
allene in these conditions is not favored, as the hydrogen atoms of the methylene group 
adjacent to the triple bond are not as acidic as are those of the propargylic position. This also 
confirmed that the attack of the enolate to the triple bond, which would eventually lead to the 
formation of the pyrrolic ring, is not favored. In light of these results, a study similar to that 
described in the previous section was performed. Hence, Ugi adduct 5p was dissolved in 
boiling toluene and indium(III) chloride or silver(I) perchlorate (0.05 equiv.) were added to the 
solution. These conditions favored the 5-exo-dig cyclization reaction, driving to the 
regioselective and exclusive formation of 3-methylenepyrrolidine 11a. Thus, we chose the 
safer indium(III) chloride as catalyst affording thereby the corresponding 3-
methylenepyrrolidine in good yields (Scheme 7, Table 5).
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Scheme 7. Synthesis of 3-methylenepyrrolidines 11a-c from Ugi adducts 5p-r.
Table 5. Results for the synthesis of 3-methylenepyrrolidines 11a-c from Ugi adducts 5p-r.
Entry 5 (R1, R2, R4) 11 (%)
1 5p (H, H, cC6H11) 11a (88)
2 5q (H, H, tBu) 11b (78)
3 5r (Cl, H, cC6H11) 11c (70)
The final cyclisation step furnishing the diazepine ring was carried out in a similar way 
for all the different pyrrolo systems, 6, 7 and 11. Reduction of the nitro group with tin(II) 
chloride in the presence of HCl in hot ethanol lead to a spontaneous intramolecular 
cyclization.17 The generated amino group undergo a nucleophilic addition to the carbonyl 
group of the molecule giving rise to an imine fragment. This process generated compounds 
12a-r in good to moderate yields (Scheme 8).
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12b (80%) 12c (80%)
12d (94%) 12e (95%) 12f (70%)
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Scheme 8. Synthesis of pyrrolobenzodiazepine-5-ones 12a-r from different pyrrolo systems.
X-ray diffraction studies of compound 12i showed that the conformation adopted by 
these systems is determined by the configuration of the stereogenic centre C3 (3S-(M)- and 
3R-(P)-conformers), as the largest substituent, the amide group derived from the isocyanide 
component in the Ugi reaction, prefers the pseudoaxial orientation (Figure 4).30
Figure 4. Crystal packing in the X-ray structure of compound 12i. Hydrogen atoms and two 
chloroform molecules have been omitted for the sake of simplicity. The ORTEP plot is at the 
30% probability level. The molecule on the left side of the image is the 3R-(P)- conformer, 
while that on the right side is the 3S-(M)- conformer.
Conclusion
In this work we have described the use of Ugi/post-condensation methodologies to provide 
straightforward access to three novel families of pyrrolobenzodiazepine-5-ones. Selecting the 
appropriate amine, it is possible to obtain saturated and unsaturated pyrrolic cores bearing 
endo or exo unsaturations in just three steps. This methodology represents a remarkable 
improvement with respect to those starting from acyclic compounds previously reported, as 
the starting materials are affordable and commercially available, and there is no need for 
derivatization, neither to use protecting groups. This allows the syntheses of three different 
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pyrrolobenzodiazepine-5-one families with high atom economy and high to moderate global 
yields.
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Melting points have not been corrected. 1H and 13C NMR spectra were recorded in CDCl3 at 300 
and 75 MHz, respectively, on a Varian Mercury 300 system; DEPT-135 experiments were 
conducted to assign carbon-13 signals. Chemical shifts are reported in parts per million with 
respect to residual solvent protons and coupling constants in hertz. High resolution mass 
spectra were recorded in positive ion mode by electronic impact (EI; Agilent 7010 mass 
spectrometer with a triple quadrupole analizer) at 70 eV or electrospray ionization (ESI; Agilent 
6545 with a quadrupole-time-of-flight analyzer).
General procedure for the synthesis of Ugi adducts 5b,f,j-r. The corresponding amine 1a-c 
(1.0 mmol, 1.0 equiv.) (3-bromopropylamine 1a should be obtained from the treatment of the 
commercial 3-bromopropylamine hydrobromide (1.1 mmol, 1.1 equiv.) with sodium hydroxide 
(1.0 mmol, 1.0 equiv.) in methanol) and the corresponding arylglyoxal 3a-d (1.0 mmol, 1.0 
equiv., 0.1 M) which were dissolved in methanol (10 mL) and the resulting solution was stirred 
at room temperature for 15 minutes to preform the imine. Subsequently, the corresponding 2-
nitrobenzoic acid 2a-c (1.0 mmol, 1.0 equiv.) and isocyanide 4a-c (1.0 mmol, 1.0 equiv.) 
derivatives were added, and the mixture was stirred at room temperature for 24 hours. The 
precipitate formed, corresponding to the different Ugi adducts 5, was isolated by vacuum 
filtration and dried. Note: as two rotamers are observed in the NMR spectra of these 
compounds, the terms “major” and “minor” are used to indicate to which of the rotamers the 
corresponding signal is assigned.
(E)-N-(3-Bromopropyl)-N-(3-(cyclohexylamino)-1-hydroxy-3-oxo-1-(p-tolyl)prop-1-en-2-yl)-2-
nitrobenzamide (5b). White solid. Yield: 381 mg, 70%. M. p. 96-97 oC (as 85:15 rotamer 
mixture). 1H NMR (300 MHz, CDCl3) δ (major rotamer): 15.32 (s, 1H, OH), 8.22 (d, J = 8.6 Hz, 
1H), 7.79-7.02 (m, 7H), 6.67 (d, J = 8.4 Hz, 1H, NH), 3.95-3.79 (m, 1H), 3.61-3.34 (m, 1H), 3.23-
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3.11 (m, 1H), 3.05-2.88 (m, 2H), 2.43 (s, 3H), 2.07-1.15 (m, 12H). 13C NMR {DEPT-135} (75 MHz, 
CDCl3) δ (major rotamer): 171.5 (Cq), 169.2 (Cq), 141.0 (Cq), 135.0 (CH), 132.9 (Cq), 131.7 (Cq), 
129.9 (CH), 129.2 (CH), 128.2 (CH), 127.5 (CH), 127.4 (CH), 125.3 (CH), 125.0 (Cq), 104.7 (Cq), 
50.7 (CH2), 49.0 (CH), 32.9 (CH2), 32.6 (CH2), 30.1 (CH2), 25.4 (CH2), 25.2 (CH2), 25.1 (CH2), 21.6 
(CH3). HRMS (ESI-QTOF) m/z: calculated for C26H31BrN3O5 [M+H+] 544.1442; found 544.1443.
(E)-N-(3-Bromopropyl)-5-chloro-N-(3-(cyclohexylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-
2-yl)-2-nitrobenzamide (5f). White solid. Yield: 384 mg, 68%. M. p. 145-146 oC (as 88:12 
rotamer mixture). 1H NMR (300 MHz, CDCl3) δ (major rotamer): 15.28 (s, 1H, OH), 8.17 (d, J = 
8.9 Hz, 1H), 7.59-7.50 (m, 6H), 7.09 (s, 1H), 6.57 (d, J = 7.7 Hz, 1H, NH), 3.92-3.81 (m, 1H), 3.20-
2.86 (m, 4H), 2.08-1.10 (m, 12H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ (major rotamer): 
171.6 (Cq), 169.0 (Cq), 167.6 (Cq), 142.9 (Cq), 142.0 (Cq), 134.4 (Cq), 130.9 (CH), 130.3 (CH), 
128.6 (CH), 127.6 (CH), 127.4 (CH), 126.7 (CH), 104.8 (Cq), 50.5 (CH2), 49.0 (CH), 32.9 (CH2), 
32.6 (CH2), 32.2 (CH2), 25.3 (CH2), 25.2 (CH2), 25.1 (CH2). HRMS (ESI-QTOF) m/z: calculated for 
C25H28BrClN3O5 [M+H+] 564.0895; found 564.0893.
(E)-N-(3-(Cyclohexylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-yl)-2-nitro-N-(prop-2-yn-1-
yl)benzamide (5j). Light pink solid. Yield: 309 mg, 69%. M. p. 154-156 oC (as 55:45 rotamer 
mixture). 1H NMR (300 MHz, CDCl3) δ: 15.77 (s, 1H, OH, minor), 15.37 (s, 1H, OH, major), 8.24-
6.46 (m, 10H), 5.06 (dd, J = 17.0, 2.5 Hz, 1H, minor), 4.28-4.05 (m, 2H, minor), 3.95-3.85 (m, 1H, 
major), 3.86 (dd, J = 17.0, 2.5 Hz, 1H, minor), 3.74 (dd, J = 17.9, 2.5 Hz, 1H, major), 3.75-3.65 
(m, 1H, minor), 3.55 (dd, J = 17.9, 2.5 Hz, 1H, major), 2.53 (t, J = 2.5 Hz, 1H, minor), 2.09 (t, J = 
2.5 Hz, 1H, major), 2.04-1.01 (m, 10H). 13C NMR {1H} (75 MHz, CDCl3) δ: 171.7, 170.2, 144.9, 
134.8, 134.5, 131.3, 130.5, 129.0, 128.4, 128.3, 128.3, 127.7, 127.5, 127.3, 125.3, 124.6, 106.2, 
77.6, 76.5, 74.9, 74.6, 49.3, 49.0, 42.6, 41.1, 32.7, 32.6, 32.2, 25.4, 25.3, 25.2.
(E)-N-(3-(Cyclohexylamino)-1-hydroxy-3-oxo-1-(p-tolyl)prop-1-en-2-yl)-2-nitro-N-(prop-2-yn-
1-yl)benzamide (5k). White solid. Yield: 364 mg, 79%. M. p. 178-180 oC (as 55:45 rotamer 
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mixture). 1H NMR (300 MHz, CDCl3) δ: 15.74 (s, 1H, OH, major), 15.38 (s, 1H, OH, minor), 8.27-
6.56 (m, 9H), 5.07 (dd, J = 17.0, 2.5 Hz, 1H, major), 4.27-4.08 (m, 2H, minor), 3.83 (dd, J = 17.0, 
2.5 Hz, 1H, major), 3.99-3.77 (m, 1H, minor), 3.76 (dd, J = 18.0, 2.5 Hz, 1H, minor), 3.75-3.60 
(m, 1H, major), 3.54 (dd, J = 18.0, 2.5 Hz, 1H, minor), 2.51 (t, J = 2.5 Hz, 1H, major), 2.43 (s, 3H, 
major), 2.43 (s, 3H, minor), 2.10 (t, J = 2.5 Hz, 1H, minor), 2.03-0.83 (m, 10H). 13C NMR {1H} (75 
MHz, CDCl3) δ: 171.7, 170.1, 169.4, 168.9, 145.3, 144.5, 141.9, 140.7, 134.9, 134.6, 133.5, 
133.1, 131.6, 131.3, 131.1, 130.6, 130.5, 130.2, 129.7, 129.3, 129.0, 128.5, 128.2, 127.7, 127.4, 
127.3, 125.3, 124.9, 124.6, 110.0, 107.2, 106.0, 77.7, 76.6, 74.8, 74.6, 49.2, 49.0, 49.0, 42.6, 
40.9, 32.7, 32.6, 32.6, 32.3, 25.4, 25.3, 25.2, 25.1, 25.0, 25.0, 24.7, 21.7, 21.6.
(E)-N-(3-(Cyclohexylamino)-1-hydroxy-1-(4-methoxyphenyl)-3-oxoprop-1-en-2-yl)-2-nitro-N-
(prop-2-yn-1-yl)benzamide (5l). White solid. Yield: 224 mg, 47%. M. p. 170-172 oC (as 55:45 
rotamer mixture). 1H NMR (300 MHz, CDCl3) δ: 15.79 (s, 1H, OH, major), 15.40 (s, 1H, OH, 
minor), 8.33-6.57 (m, 9H), 5.08 (dd, J = 17.0, 2.5 Hz, 1H, major), 5.08 (dd, J = 17.0, 2.5 Hz, 1H, 
major), 4.30-4.04 (m, 2H, minor), 3.88 (s, 3H, minor), 3.86 (s, 3H, major), 3.78 (dd, J = 17.9, 2.5 
Hz, 1H, minor), 3.95-3.80 (m, 1H, minor), 3.75-3.55 (m, 1H, major), 3.57 (dd, J = 17.9, 2.5 Hz, 
1H, minor), 2.50 (t, J = 2.5 Hz, 1H, major), 2.09 (t, J = 2.5 Hz, 1H, major), 2.10-0.94 (m, 10H). 13C 
NMR {1H} (75 MHz, CDCl3) δ: 171.4, 169.5, 164.0, 161.8, 161.3, 134.6, 133.4, 130.9, 130.6, 
130.5, 130.2, 129.6, 129.2, 128.5, 128.0, 127.4, 125.7, 125.3, 124.9, 124.6, 114.4, 113.9, 113.7, 
106.6, 77.7, 74.7, 74.5, 55.5, 55.5, 49.2, 49.1, 49.0, 42.6, 40.7, 32.7, 32.6, 32.3, 25.4, 25.3, 25.1, 
25.0, 24.8.
(E)-N-(3-(tert-Butylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-yl)-2-nitro-N-(prop-2-yn-1-
yl)benzamide (5m). White solid. Yield: 223 mg, 53%. M. p. 186-188 oC (as 55:45 rotamer 
mixture). 1H NMR (300 MHz, CDCl3) δ: 15.84 (s, 1H, OH, minor), 15.51 (s, 1H, OH, major), 8.28-
6.22 (m, 10H), 5.05 (dd, J = 17.1, 2.5 Hz, 1H, minor), 4.31-4.10 (m, 2H, minor), 3.95 (dd, J = 
17.1, 2.5 Hz, 1H, minor), 3.75 (dd, J = 17.9, 2.5 Hz, 1H, major), 3.56 (d, J = 17.9, 2.5 Hz, 1H, 
major), 2.55 (t, J = 2.5 Hz, 1H, minor), 2.13 (t, J = 2.5 Hz, 1H, major), 1.52 (s, 9H, minor), 1.42 (s, 
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9H, major). 13C NMR {1H} (75 MHz, CDCl3) δ: 171.9, 170.6, 170.2, 169.8, 168.2, 144.8, 144.4, 
134.8, 134.6, 133.6, 131.1, 130.7, 130.4, 130.3, 130.1, 128.9, 128.6, 128.4, 128.3, 127.7, 127.4, 
127.2, 125.1, 124.9, 124.3, 107.9, 106.6, 77.7, 76.7, 75.0, 74.5, 52.7, 52.4, 42.7, 41.5, 28.8, 
28.4, 28.3.
(E)-5-Chloro-N-(3-(cyclohexylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-yl)-2-nitro-N-
(prop-2-yn-1-yl)benzamide (5n). Light pink solid. Yield: 347 mg, 72%. M. p. 144-146 oC (as 
57:43 rotamer mixture). 1H NMR (300 MHz, CDCl3) δ: 15.76 (s, 1H, OH, major), 15.29 (s, 1H, 
OH, minor), 8.19-6.93 (m, 8H), 6.66 (d, J = 7.9 Hz, 1H, minor), 6.59 (d, J = 7.7 Hz, 1H, major), 
5.88 (d, J = 2.4 Hz, 1H, major), 5.04 (dd, J = 17.0, 2.4 Hz, 1H, major), 4.27-4.10 (m, 2H, minor), 
4.02 (dd, J = 17.0, 2.4 Hz, 1H, major), 3.97-3.81 (m, 1H, minor), 3.74 (dd, J = 18.0, 2.5 Hz, 1H, 
minor), 3.74 (dd, J = 18.0, 2.5 Hz, 1H, minor), 3.73-3.65 (m, 1H, major), 3.57 (dd, J = 18.0, 2.5 
Hz, 1H, minor), 2.61 (t, J = 2.5 Hz, 1H, major), 2.13 (t, J = 2.5 Hz, 1H, minor), 2.08-1.06 (m, 10H). 
13C NMR {1H} (75 MHz, CDCl3) δ: 171.8, 171.6, 169.2, 168.7, 166.7, 166.6, 140.5, 134.4, 133.8, 
133.6, 133.0, 131.2, 130.6, 130.5, 130.2, 129.2, 128.8, 128.6, 128.5, 128.4, 127.6, 127.3, 127.3, 
126.6, 125.7, 110.0, 107.2, 106.3, 75.4, 74.8, 49.5, 49.0, 42.7, 42.1, 32.7, 32.2, 25.4, 25.1, 25.0, 
24.9.
(E)-4-Chloro-N-(3-(cyclohexylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-yl)-2-nitro-N-
(prop-2-yn-1-yl)benzamide (5o). White solid. Yield: 337 mg, 70%. M. p. 168-170 oC (as 52:48 
rotamer mixture). 1H NMR (300 MHz, CDCl3) δ: 15.80 (s, 1H, OH, major), 15.32 (s, 1H, OH, 
minor), 8.33-7.11 (m, 7H), 6.93 (d, J = 8.2 Hz, 1H, minor), 6.64 (d, J = 8.1 Hz, 1H), 6.27 (d, J = 8.3 
Hz, 1H, major), 5.04 (dd, J = 17.0, 2.4 Hz, 1H, major), 4.29-4.03 (m, 2H, minor), 3.89 (dd, J = 
17.0, 2.4 Hz, 1H, major), 3.95-3.85 (m, 1H, minor), 3.80-3.67 (m, 1H, major), 3.72 (dd, J = 18.0, 
2.5 Hz, 1H, minor), 3.56 (dd, J = 18.0, 2.5 Hz, 1H, minor), 2.55 (t, J = 2.5 Hz, 1H, major), 2.10 (t, J 
= 2.5 Hz, 1H, minor), 2.00-0.92 (m, 10H). 13C NMR {1H} (75 MHz, CDCl3) δ: 171.8, 171.8, 170.5, 
169.2, 168.7, 145.4, 136.6, 136.1, 134.9, 134.4, 133.4, 131.4, 130.5, 129.4, 129.0, 128.6, 128.4, 
Page 21 of 42
ACS Paragon Plus Environment






























































127.7, 127.4, 125.4, 124.7, 106.3, 77.5, 76.4, 75.1, 74.8, 49.4, 49.0, 42.7, 41.4, 32.7, 32.6, 32.3, 
25.4, 25.3, 25.1, 25.0, 24.9.
(E)-N-(But-3-yn-1-yl)-N-(3-(cyclohexylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-yl)-2-
nitrobenzamide (5p). White solid. Yield: 401 mg, 87%. M. p. 178-180 oC (as 84:16 rotamer 
mixture). 1H NMR (300 MHz, CDCl3) δ (major rotamer): 15.41 (s, 1H, OH), 8.24-7.08 (m, 9H), 
6.67 (d, J = 7.8 Hz, 1H, NH), 3.95-3.78 (m, 1H), 3.23-3.12 (m, 1H), 2.97-2.86 (m, 1H), 2.25-0.70 
(m, 13H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ (major rotamer): 171.6 (Cq), 169.2 (Cq), 168.7 
(Cq), 145.0 (Cq), 134.8 (CHAr), 134.4 (Cq), 132.7 (Cq), 130.7 (CHAr), 130.4 (CHAr), 128.5 (CHAr), 
127.4 (CH), 127.1 (CH), 125.4 (CH), 104.6 (Cq), 80.0 (Cq), 70.6 (CH), 51.1 (CH2), 49.1 (CH), 32.8 
(CH2), 32.6 (CH2), 25.4 (CH2), 25.2 (CH2), 25.1 (CH2), 17.6 (CH2). HRMS (ESI-QTOF) m/z: 
calculated for C26H28N3O5 [M+H+] 462.2023; found 462.2027.
(E)-N-(But-3-yn-1-yl)-N-(3-(tert-butylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-yl)-2-
nitrobenzamide (5q). White solid. Yield: 357 mg, 82%. M. p. 124-126 oC (as 82:18 rotamer 
mixture). 1H NMR (300 MHz, CDCl3) δ (major rotamer): 15.59 (s, 1H, OH), 8.22-7.02 (m, 9H), 
6.55 (s, 1H, NH), 3.56-1.99 (m, 4H), 1.85 (t, J = 2.6 Hz, 1H), 1.52 (s, 9H). 13C NMR {DEPT-135} (75 
MHz, CDCl3) δ (major rotamer): 171.8 (Cq), 170.2 (Cq), 168.8 (Cq), 144.8 (Cq), 134.6 (CH), 132.6 
(Cq), 130.3 (CH), 129.0 (CH), 128.5 (CH), 127.4 (CH), 127.1 (CH), 125.2 (CH), 104.9 (Cq), 80.1 
(Cq), 70.6 (CH), 52.5 (Cq), 51.2 (CH2), 28.8 (CH3), 17.5 (CH2). HRMS (EI) m/z: calculated for 
C24H26N3O5 [M+H+] 436.1867; found 436.1874.
(E)-N-(But-3-yn-1-yl)-4-chloro-N-(3-(cyclohexylamino)-1-hydroxy-3-oxo-1-phenylprop-1-en-2-
yl)-2-nitrobenzamide (5r). White solid. Yield: 407 mg, 82%. M. p. 122-124 oC (as 82:18 rotamer 
mixture). 1H NMR (300 MHz, CDCl3) δ (major rotamer): 15.38 (s, 1H, OH), 8.20-6.97 (m, 8H), 
6.57 (d, J = 8.0 Hz, 1H, NH), 3.97-3.72 (m, 1H), 3.20-3.10 (m, 1H), 2.95-2.84 (m, 1H), 2.25-0.81 
(m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ (major rotamer): 171.6 (Cq), 169.0 (Cq), 167.8 
(Cq), 136.3 (Cq), 134.9 (CHAr), 134.3 (Cq), 130.9 (Cq), 130.7 (CHAr), 129.2 (CHAr), 128.6 (CHAr), 
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128.3 (CHAr), 127.7 (CHAr), 127.3 (CHAr), 125.5 (CHAr), 104.5 (Cq), 80.0 (CH), 70.8 (CH), 51.1 
(CH2), 48.9 (CH), 32.7 (CH2), 32.6 (CH2), 29.6 (CH2), 25.4 (CH2), 25.1 (CH2), 17.5 (CH2). HRMS (EI) 
m/z: calculated for C26H27ClN3O5 [M+H+] 496.1634; found 496.1641.
General procedure for the synthesis of pyrrolidines 6a-i. 1.0 mmol (1.0 equiv.) of sodium 
hydroxide was added to a solution of 3-bromopropylamine hydrobromide 1a (1.1 mmol, 1.1 
equiv.) in methanol (10 mL). Subsequently, the corresponding arylglyoxal 3a-d (1.0 mmol, 1.0 
equiv., 0.1 M) was added, followed by the addition of the corresponding 2-nitrobenzoic acid 
2a-c (1.0 mmol, 1.0 equiv.) and the corresponding isocyanide 4a-c (1.0 mmol, 1.0 equiv.). The 
resulting solution was stirred at room temperature for 24 hours and, then, cesium carbonate 
(1.5 mmol, 1.5 equiv.) was added. The mixture was stirred at room temperature for one hour 
and the solvent was removed under reduced pressure. The raw product was dissolved in 
dichloromethane and washed with acidified water. The organic phase was dried over 
anhydrous sodium sulfate, filtered and concentrated to dryness, thus yielding the 
corresponding pyrrolidine 6a-i.
2-Benzoyl-N-cyclohexyl-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (6a). Light brown solid. 
Yield: 386 mg, 86%. M. p. 133-134 oC. 1H NMR (300 MHz, CDCl3) δ: 8.33 (d, J = 7.8 Hz, 1H), 8.15 
(d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.3 Hz, 2H), 7.73 (t, J = 7.5 Hz, 1H), 7.66-7.44 (m, 3H), 7.37 (t, J = 
7.5 Hz, 2H), 3.73-3.65 (m, 1H), 3.42-3.14 (m, 3H), 2.13-1.77 (m, 4H), 1.54-1.00 (m, 8H), 0.79-
0.68 (m, 1H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 199.2 (Cq), 171.9 (Cq), 171.2 (Cq), 148.4 
(Cq), 140.1 (Cq), 139.1 (CHAr), 137.1 (Cq), 136.9 (CHAr), 134.4 (CHAr), 132.5 (CHAr), 132.3 (CHAr), 
132.2 (CHAr), 128.9 (CHAr), 82.8 (Cq), 55.3 (CH2), 52.6 (CH), 40.2 (CH2), 36.0 (CH2), 35.7 (CH2), 
29.6 (CH2), 29.0 (CH2), 28.5 (CH2), 28.2 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H28N3O5 
[M+H+] 450.2023; found 450.2019.
N-Cyclohexyl-2-(4-methylbenzoyl)-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (6b). Light 
brown solid. Yield: 412 mg, 89%. M. p. 112-114 oC. 1H NMR (300 MHz, CDCl3) δ: 8.39 (d, J = 7.4 
Page 23 of 42
ACS Paragon Plus Environment






























































Hz, 1H), 8.14 (d, J = 8.3 Hz, 1H), 7.79 (d, J = 8.3 Hz, 2H), 7.73-7.51 (m, 3H), 7.16 (d, J = 8.3 Hz, 
2H), 3.80-3.64 (m, 1H), 3.39-3.21 (m, 3H), 2.32 (s, 3H), 2.11-1.00 (m, 12H), 0.84-0.75 (m, 1H). 
13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 193.9 (Cq), 167.7 (Cq), 167.1 (Cq), 144.1 (Cq), 143.7 
(Cq), 134.9 (CHAr), 132.9 (Cq), 130.2 (CHAr), 128.9 (CHAr), 128.4 (CHAr), 128.0 (CHAr), 124.6 (CHAr), 
78.6 (Cq), 51.2 (CH2), 48.4 (CH), 36.0 (CH2), 31.8 (CH2), 31.6 (CH2), 25.4 (CH2), 24.7 (CH2), 24.2 
(CH2), 24.0 (CH2), 21.6 (CH3). HRMS (ESI-QTOF) m/z: calculated for C26H30N3O5 [M+H+] 
464.2180; found 464.2177.
2-(4-Chlorobenzoyl)-N-cyclohexyl-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (6c). Light 
brown solid. Yield: 392 mg, 81%. M. p. 175-176 oC. 1H NMR (300 MHz, CDCl3) δ: 8.29 (d, J = 7.5 
Hz, 1H), 8.13 (d, J = 8.3 Hz, 1H), 7.80 (d, J = 8.3 Hz, 2H), 7.71 (app. td, ddd, J = 7.5, 7.5, 1.8 Hz, 
1H), 7.58-7.51 (m, 2H), 7.31 (d, J = 8.3 Hz, 2H), 3.71-3.59 (m, 1H), 3.35-3.21 (m, 3H), 2.26-0.69 
(m, 13H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 193.9 (Cq), 167.7 (Cq), 166.9 (Cq), 144.1 (Cq), 
139.1 (Cq), 134.9 (CHAr), 134.2 (Cq), 132.6 (Cq), 130.3 (CHAr), 129.7 (CHAr), 128.5 (CHAr), 127.9 
(CHAr), 124.7 (CHAr), 78.5 (Cq), 51.0 (CH2), 48.5 (CH), 36.2 (CH2), 31.8 (CH2), 31.6 (CH2), 25.4 
(CH2), 24.7 (CH2), 24.2 (CH2), 24.0 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H27ClN3O5 
[M+H+] 484.1634; found 484.1631.
2-Benzoyl-N-(tert-butyl)-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (6d). Light brown solid. 
Yield: 339 mg, 80%. M. p. 106-107 oC. 1H NMR (300 MHz, CDCl3) δ: 8.35 (s, 1H), 8.20 (dd, J = 
8.3, 1.2 Hz, 1H), 7.92-7.89 (m, 2H), 7.76 (app. td, ddd, J = 7.5, 7.5, 1.2 Hz, 1H), 7.65-7.49 (m, 
3H), 7.40 (t, J = 7.5 Hz, 2H), 3.49-3.17 (m, 3H), 2.16-1.92 (m, 3H), 1.16 (s, 9H). 13C NMR {DEPT-
135} (75 MHz, CDCl3) δ: 194.9 (Cq), 167.6 (Cq), 166.5 (Cq), 144.2 (Cq), 135.9 (Cq), 134.8 (CHAr), 
132.9 (Cq), 132.7 (CHAr), 130.2 (CHAr), 128.2 (CHAr), 128.2 (CHAr), 128.0 (CHAr), 124.7 (CHAr), 79.2 
(Cq), 51.3 (CH2), 51.2 (Cq), 35.9 (CH2), 27.9 (CH3), 24.8 (CH2). HRMS (ESI-QTOF) m/z: calculated 
for C23H26N3O5 [M+H+] 424.1867; found 424.1864.
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2-Benzoyl-N-butyl-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (6e). Light brown solid. Yield: 
368 mg, 87%. M. p. 107-108 oC. 1H NMR (300 MHz, CDCl3) δ: 8.25 (t, J = 5.1 Hz, 1H), 8.11 (d, J = 
8.0 Hz, 1H), 7.83 (d, J = 7.5 Hz, 2H), 7.69 (app. td, ddd, J = 7.5, 7.5, 1.2 Hz, 1H), 7.54-7.42 (m, 
3H), 7.34 (t, J = 7.5 Hz, 2H), 3.38-3.02 (m, 5H), 2.09-1.87 (m, 3H), 1.26-1.17 (m, 2H), 1.05-0.92 
(m, 2H), 0.65 (t, J = 7.2 Hz, 3H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 194.8 (Cq), 168.1 (Cq), 
167.6 (Cq), 144.2 (Cq), 135.8 (Cq), 134.9 (CHAr), 132.8 (CHAr), 132.6 (Cq), 130.3 (CHAr), 128.3 
(CHAr), 128.1 (CHAr), 127.8 (CHAr), 124.7 (CHAr), 78.5 (Cq), 51.0 (CH2), 39.7 (CH2), 36.0 (CH2), 30.7 
(CH2), 24.7 (CH2), 19.8 (CH2), 13.6 (CH3). HRMS (ESI-QTOF) m/z: calculated for C23H26N3O5 
[M+H+] 424.1867; found 424.1865.
2-Benzoyl-1-(5-chloro-2-nitrobenzoyl)-N-cyclohexylpyrrolidine-2-carboxamide (6f). Light 
brown solid. Yield: 406 mg, 84%. M. p. 151-152 oC. 1H NMR (300 MHz, CDCl3) δ: 8.29 (d, J = 7.9 
Hz, 1H), 8.19 (d, J = 8.8 Hz, 1H), 7.92 (d, J = 7.3 Hz, 2H), 7.68 (d, J = 2.3 Hz, 1H), 7.58-7.53 (m, 
2H), 7.44 (t, J = 7.8 Hz, 2H), 3.72-3.64 (m, 1H), 3.44-3.25 (m, 3H), 2.14-1.92 (m, 3H), 1.77-0.67 
(m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 194.6 (Cq), 166.6 (Cq), 166.2 (Cq), 142.5 (Cq), 
141.6 (Cq), 135.6 (Cq), 134.3 (Cq), 132.9 (CHAr), 130.3 (CHAr), 128.3 (CHAr), 128.1 (CHAr), 128.0 
(CHAr), 126.3 (CHAr), 78.7 (Cq), 51.1 (CH2), 48.4 (CH), 36.0 (CH2), 31.8 (CH2), 31.5 (CH2), 25.4 
(CH2), 24.8 (CH2), 24.2 (CH2), 23.9 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H27ClN3O5 
[M+H+] 484.1634; found 484.1629.
1-(4-Chloro-2-nitrobenzoyl)-N-cyclohexyl-2-(4-methylbenzoyl)pyrrolidine-2-carboxamide 
(6g). Light brown solid. Yield: 433 mg, 87%. M. p. 135-136 oC. 1H NMR (300 MHz, CDCl3) δ: 8.35 
(d, J = 7.8 Hz, 1H), 8.19 (d, J = 2.0 Hz, 1H), 7.83 (d, J = 8.0 Hz, 2H), 7.74 (dd, J = 8.2, 2.0 Hz, 1H), 
7.65 (d, J = 8.2 Hz, 1H), 7.20 (d, J = 8.0 Hz, 2H), 3.79-3.67 (m, 1H), 3.46-3.26 (m, 3H), 2.37 (s, 
3H), 2.18-1.91 (m, 3H), 1.83-0.75 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 193.7 (Cq), 
166.8 (Cq), 166.8 (Cq), 144.8 (Cq), 143.9 (Cq), 136.1 (Cq), 134.9 (CHAr), 132.7 (Cq), 131.4 (Cq), 
129.3 (CHAr), 129.0 (CHAr), 128.5 (CHAr), 124.9 (CHAr), 78.8 (Cq), 51.3 (CH2), 48.5 (CH), 36.1 (CH2), 
Page 25 of 42
ACS Paragon Plus Environment






























































31.8 (CH2), 31.6 (CH2), 25.4 (CH2), 24.8 (CH2), 24.3 (CH2), 24.0 (CH2), 21.7 (CH3). HRMS (ESI-
QTOF) m/z: calculated for C26H29ClN3O5 [M+H+] 498.1790; found 498.1781.
2-Benzoyl-N-(tert-butyl)-1-(4-chloro-2-nitrobenzoyl)pyrrolidine-2-carboxamide (6h). Light 
brown solid. Yield: 348 mg, 76%. M. p. 123-124 oC. 1H NMR (300 MHz, CDCl3) δ: 8.26 (s, 1H), 
8.15 (d, J = 2.0 Hz, 1H), 7.88-7.85 (m, 2H), 7.71 (dd, J = 8.2, 2.0 Hz, 1H), 7.58 (d, J = 8.2 Hz, 1H), 
7.49 (tt, J = 7.2, 2.0 Hz, 1H), 7.37 (t, J = 7.2 Hz, 2H), 3.41-3.22 (m, 3H), 2.14-1.91 (m, 3H), 1.12 
(s, 9H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 194.5 (Cq), 166.7 (Cq), 166.3 (Cq), 144.8 (Cq), 
136.1 (Cq), 135.6 (Cq), 134.9 (CHAr), 132.8 (CHAr), 131.2 (Cq), 129.2 (CHAr), 128.3 (CHAr), 128.2 
(CHAr), 124.9 (CHAr), 79.3 (Cq), 51.3 (Cq), 51.2 (CH2), 35.9 (CH2), 27.9 (CH3), 24.8 (CH2). HRMS 
(ESI-QTOF) m/z: calculated for C23H25ClN3O5 [M+H+] 458.1477; found 458.1475.
1-(4-Chloro-2-nitrobenzoyl)-N-cyclohexyl-2-(4-methoxybenzoyl)pyrrolidine-2-carboxamide 
(6i). Light brown solid. Yield: 442 mg, 86%. M. p. 112-113 oC. 1H NMR (300 MHz, CDCl3) δ: 8.45 
(d, J = 7.3 Hz, 1H), 8.19 (s, 1H), 7.98-7.94 (m, 2H), 7.77-7.67 (m, 2H), 6.96-6.84 (m, 2H), 3.84 (s, 
3H), 3.82-3.69 (m, 1H), 3.45-3.29 (m, 3H), 2.21-1.93 (m, 3H), 1.86-0.81 (m, 10H). 13C NMR 
{DEPT-135} (75 MHz, CDCl3) δ: 191.9 (Cq), 167.0 (Cq), 166.9 (Cq), 163.5 (Cq), 144.8 (Cq), 136.0 
(Cq), 134.9 (CHAr), 131.5 (Cq), 131.1 (CHAr), 129.4 (CHAr), 127.8 (Cq), 124.9 (CHAr), 113.6 (CHAr), 
78.8 (Cq), 55.5 (CH3), 51.4 (CH2), 48.5 (CH), 36.1 (CH2), 31.9 (CH2), 31.8 (CH2), 25.4 (CH2), 24.7 
(CH2), 24.3 (CH2), 24.1 (CH2). HRMS (ESI-QTOF) m/z: calculated for C26H29ClN3O6 [M+H+] 
514.1739; found  514.1737.
General procedure for the synthesis of 3-pyrrolines 7a-f. A mixture of the corresponding Ugi 
adduct 5j-o (1.0 mmol, 1.0 equiv., 0.1 M) and Na2CO3 (1.0 mmol, 1.0 equiv.) in boiling ethanol 
(10 mL) was stirred for 6 hours, after which the solvent was removed by rotary evaporation. 
The raw product was dissolved in dichloromethane and washed with acidified water. The 
organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to dryness, 
thus yielding the corresponding 3-pyrrolines 7a-f.
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2-Benzoyl-N-cyclohexyl-1-(2-nitrobenzoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide (7a). Sticky 
brown solid. Yield: 362 mg, 81%. 1H NMR (300 MHz, CDCl3) δ: 8.23-8.20 (m, 2H), 7.96-7.92 (m, 
2H), 7.71 (tt, J = 7.5, 1.2 Hz, 1H), 7.62-7.55 (m, 2H), 7.47-7.42 (m, 2H), 7.20 (d, J = 7.5 Hz, 1H), 
6.33 (dt, J = 6.4, 2.3 Hz, 1H), 6.04 (dt, J = 6.4, 2.3 Hz, 1H), 4.19-4.07 (m, 2H), 3.88-3.77 (m, 1H), 
2.04-0.79 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 193.7 (Cq), 167.3 (Cq), 167.1 (Cq), 
144.2 (Cq), 136.8 (Cq), 135.0 (CHAr), 132.6 (CHAr), 132.1 (Cq), 130.5 (CHAr), 129.6 (CH), 128.3 
(CHAr), 128.2 (CHAr), 127.8 (CHAr), 127.1 (CH), 124.7 (CHAr), 84.9 (Cq), 56.3 (CH2), 48.5 (CH), 32.1 
(CH2), 32.0 (CH2), 25.5 (CH2), 24.4 (CH2), 24.3 (CH2). HRMS (ESI-QTOF) m/z: calculated for 
C25H26N3O5 [M+H+] 448.1867; found 448.1872.
N-Cyclohexyl-2-(4-methylbenzoyl)-1-(2-nitrobenzoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide 
(7b). Sticky brown solid. Yield: 337 mg, 73%. 1H NMR (300 MHz, CDCl3) δ: 8.25 (d, J = 7.8 Hz, 
1H), 8.19 (d, J = 8.3 Hz, 1H), 7.86 (d, J = 8.3 Hz, 2H), 7.70 (app. td, ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 
7.57 (app. td, ddd, J = 7.8, 7.8, 1.5 Hz, 1H), 7.26 (dd, J = 7.8, 1.2 Hz, 1H), 7.22 (d, J = 8.3 Hz, 2H), 
6.27 (dt, J = 6.4, 2.1 Hz, 1H), 5.98 (dt, J = 6.4, 2.1 Hz, 1H), 4.10 (t, J = 2.1 Hz, 2H), 3.86-3.74 (m, 
1H), 2.39 (s, 3H), 2.05-0.76 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 192.4 (Cq), 167.4 
(Cq), 167.3 (Cq), 144.2 (Cq), 143.7 (Cq), 135.0 (CH), 133.5 (Cq), 132.3 (Cq), 130.4 (CH), 129.7 
(CH), 129.0 (CH), 128.6 (CH), 128.0 (CH), 126.8 (CH), 124.7 (CH), 85.1 (Cq), 56.4 (CH2), 48.5 
(CH), 32.1 (CH2), 32.0 (CH2), 25.5 (CH2), 24.4 (CH2), 24.4 (CH2), 21.7 (CH3). HRMS (ESI-QTOF) 
m/z: calculated for C26H28N3O5 [M+H+] 462.2023; found 462.2036.
N-Cyclohexyl-2-(4-methoxybenzoyl)-1-(2-nitrobenzoyl)-2,5-dihydro-1H-pyrrole-2-
carboxamide (7c). Sticky brown solid. Yield: 391 mg, 82%. 1H NMR (300 MHz, CDCl3) δ: 8.35 (d, 
J = 7.5 Hz, 1H), 8.19 (d, J = 8.3 Hz, 1H), 8.00 (d, J = 8.3 Hz, 2H), 7.72 (t, J = 7.5 Hz, 1H), 7.57 (t, J = 
7.5 Hz, 1H), 7.42 (d, J = 7.5 Hz, 1H), 6.89 (d, J = 8.3 Hz, 2H), 6.25 (d, J = 6.3 Hz, 1H), 5.94 (d, J = 
6.3 Hz, 1H), 4.09 (s, 2H), 3.90-3.73 (m, 1H), 3.83 (s, 3H), 2.07-0.73 (m, 10H). 13C NMR {DEPT-
135} (75 MHz, CDCl3) δ: 190.5 (Cq), 167.5 (Cq), 163.4 (Cq), 144.2 (Cq), 135.0 (CH), 132.5 (Cq), 
131.1 (CH), 130.4 (CH), 129.7 (CH), 128.3 (Cq), 128.1 (CH), 126.5 (CH), 124.7 (CH), 113.6 (CH), 
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85.1 (Cq), 56.5 (CH2), 55.5 (CH3), 48.5 (CH), 32.0 (CH2), 25.5 (CH2), 24.4 (CH2), 24.3 (CH2). HRMS 
(ESI-QTOF) m/z: calculated for C26H28N3O6 [M+H+] 478.1973; found 478.1976.
2-Benzoyl-N-(tert-butyl)-1-(2-nitrobenzoyl)-2,5-dihydro-1H-pyrrole-2-carboxamide (7d). 
Sticky brown solid. Yield: 303 mg, 72%. 1H NMR (300 MHz, CDCl3) δ: 8.22 (s, 1H), 8.18 (dd, J = 
8.2, 1.2 Hz, 1H), 7.92 (d, J = 7.5 Hz, 2H), 7.68 (app. td, ddd, J = 7.5, 7.5, 1.2 Hz, 1H), 7.61-7.51 
(m, 2H), 7.42 (t, J = 7.5 Hz, 2H), 7.09 (dd, J = 7.5, 1.2 Hz, 1H), 6.27 (dt, J = 6.3, 2.2 Hz, 1H), 6.01 
(dt, J = 6.3, 2.2 Hz, 1H), 4.18-3.95 (m, 2H), 1.30 (s, 9H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 
193.4 (Cq), 167.3 (Cq), 167.1 (Cq), 144.2 (Cq), 136.5 (Cq), 135.0 (CH), 132.7 (CH), 132.1 (Cq), 
130.5 (CH), 129.7 (CH), 128.3 (CH), 128.3 (CH), 127.8 (CH), 127.0 (CH), 124.7 (CH), 85.6 (Cq), 
56.4 (CH2), 51.5 (Cq), 28.2 (CH3). HRMS (ESI-QTOF) m/z: calculated for C23H24N3O5 [M+H+] 
422.1710; found 422.1714.
2-Benzoyl-1-(5-chloro-2-nitrobenzoyl)-N-cyclohexyl-2,5-dihydro-1H-pyrrole-2-carboxamide 
(7e). Sticky brown solid. Yield: 371 mg, 77%. 1H NMR (300 MHz, CDCl3) δ: 8.12 (d, J = 8.8 Hz, 
1H), 8.10 (d, J = 8.8 Hz, 1H), 7.90-7.86 (m, 2H), 7.60-7.40 (m, 4H), 6.99 (s, 1H), 6.30 (dt, J = 6.4, 
2.1 Hz, 1H), 6.04 (dt, J = 6.4, 2.1 Hz, 1H), 4.19-4.07 (m, 2H), 3.85-3.74 (m, 1H), 2.00-0.73 (m, 
10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 193.0 (Cq), 166.8 (Cq), 165.8 (Cq), 142.4 (Cq), 
141.8 (Cq), 136.7 (Cq), 133.5 (Cq), 132.8 (CH), 130.5 (CH), 129.6 (CH), 128.4 (CH), 128.3 (CH), 
128.0 (CH), 127.1 (CH), 126.2 (CH), 85.1 (Cq), 56.3 (CH2), 48.5 (CH), 32.1 (CH2), 32.0 (CH2), 25.5 
(CH2), 24.4 (CH2), 24.3 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H25ClN3O5 [M+H+] 
482.1477; found 482.1488.
2-Benzoyl-1-(4-chloro-2-nitrobenzoyl)-N-cyclohexyl-2,5-dihydro-1H-pyrrole-2-carboxamide 
(7f). Sticky brown solid. Yield: 419 mg, 87%. 1H NMR (300 MHz, CDCl3) δ: 8.20-8.07 (m, 2H), 
7.87 (d, J = 7.5 Hz, 2H), 7.66-7.62 (m, 1H), 7.53 (t, J = 7.5 Hz, 1H), 7.40 (t, J = 7.5 Hz, 2H), 7.10 
(d, J = 8.2 Hz, 1H), 6.26 (d, J = 6.1 Hz, 1H), 6.02 (d, J = 6.1 Hz, 1H), 4.16-4.04 (m, 2H), 3.83-3.71 
(m, 1H), 2.05-0.70 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 193.7 (Cq), 166.8 (Cq), 
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166.3 (Cq), 144.7 (Cq), 136.6 (Cq), 136.4 (Cq), 135.0 (CH), 132.7 (CH), 130.4 (Cq), 129.5 (CH), 
129.2 (CH), 128.3 (CH), 128.2 (CH), 127.2 (CH), 124.8 (CH), 85.0 (Cq), 56.3 (CH2), 48.5 (CH), 32.1 
(CH2), 32.0 (CH2), 25.5 (CH2), 24.4 (CH2), 24.3 (CH2). HRMS (ESI-QTOF) m/z: calculated for 
C25H25ClN3O5 [M+H+] 482.1477; found 482.1483.
General procedure for the synthesis of 3-methylenepyrrolidines 11a-c. A mixture of the 
corresponding Ugi adduct 5p-r (1.0 mmol, 1.0 equiv., 0.1 M) and InCl3 (0.05 mmol, 0.05 equiv.) 
in toluene (10 mL) was heated to reflux for two hours. After removing the solvent by rotary 
evaporation, the raw product was dissolved in dichloromethane and washed with slightly basic 
water. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated 
to dryness, giving the corresponding 3-methylenepyrrolidines 11a-c.
2-Benzoyl-N-cyclohexyl-3-methylene-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (11a). 
White solid. Yield: 406 mg, 88%. M. p. 158-160 oC. 1H NMR (300 MHz, CDCl3) δ: 8.34 (d, J = 7.7 
Hz, 1H, NH), 8.10 (dd, J = 8.1, 1.2 Hz, 1H), 7.71-7.40 (m, 7H), 7.00 (s, 1H), 5.40-5.22 (m, 2H), 
3.95-3.74 (m, 1H), 3.66 (td, J = 9.9, 4.8 Hz, 1H), 3.58-3.49 (m, 1H), 3.20-3.07 (m, 1H), 3.03-2.90 
(m, 1H), 2.00-0.82 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 198.7 (Cq), 166.7 (Cq), 
166.6 (Cq), 144.9 (Cq), 144.4 (Cq), 137.3 (Cq), 134.4 (CHAr), 131.9 (CHAr), 131.8 (Cq), 130.1 
(CHAr), 128.3 (CHAr), 128.1 (CHAr), 127.9 (CHAr), 124.3 (CHAr), 111.8 (CH2), 78.5 (Cq), 48.8 (CH), 
47.8 (CH2), 32.3 (CH2), 32.2 (CH2), 31.0 (CH2), 25.6 (CH2), 24.6 (CH2), 24.5 (CH2). HRMS (ESI-
QTOF) m/z: calculated for C26H28N3O5 [M+H+] 462.2023; found 462.2033.
2-Benzoyl-N-(tert-butyl)-3-methylene-1-(2-nitrobenzoyl)pyrrolidine-2-carboxamide (11b). 
Brown solid. Yield: 340 mg, 78%. M. p. 140-142 oC. 1H NMR (300 MHz, CDCl3) δ: 8.24 (br s, 1H, 
NH), 8.05 (dd, J = 8.2, 1.4 Hz, 1H), 7.69-7.36 (m, 7H), 6.78 (d, J = 6.7 Hz, 1H), 5.32 (s, 1H), 5.22 
(s, 1H), 3.61-3.45 (m, 2H), 3.14-3.02 (m, 1H), 2.98-2.86 (m, 1H), 1.39 (s, 9H). 13C NMR {DEPT-
135} (75 MHz, CDCl3) δ: 198.2 (Cq), 166.7 (Cq), 166.1 (Cq), 144.6 (Cq), 144.4 (Cq), 137.2 (Cq), 
134.5 (CHAr), 131.9 (CHAr), 131.7 (Cq), 130.2 (CHAr), 128.2 (CHAr), 127.9 (CHAr), 124.4 (CHAr), 
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112.1 (CH2), 79.3 (Cq), 51.4 (Cq), 47.8 (CH2), 31.0 (CH2), 28.4 (CH3). HRMS (ESI-QTOF) m/z: 
calculated for C24H26N3O5 [M+H+] 436.1867; found  436.1877.
2-Benzoyl-1-(4-chloro-2-nitrobenzoyl)-N-cyclohexyl-3-methylenepyrrolidine-2-carboxamide 
(11c). White solid. Yield: 347 mg, 70%. M. p. 180-182 oC. 1H NMR (300 MHz, CDCl3) δ: 8.37 (d, J 
= 6.8 Hz, 1H, NH), 8.06-8.04 (m, 1H), 7.66-7.36 (m, 6H), 6.99 (d, J = 8.3 Hz, 1H), 5.39-5.20 (m, 
2H), 3.87-3.77 (m, 1H), 3.68-3.60 (m, 1H), 3.56-3.47 (m, 1H), 3.19-3.06 (m, 1H), 3.04-2.91 (m, 
1H), 1.99-1.23 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 198.9 (Cq), 166.6 (Cq), 165.7 
(Cq), 145.0 (Cq), 144.9 (Cq), 137.3 (Cq), 136.0 (Cq), 134.4 (CHAr), 131.9 (CHAr), 130.2 (Cq), 129.7 
(CHAr), 128.0 (CHAr), 127.9 (CHAr), 124.5 (CHAr), 111.6 (CH2), 78.3 (Cq), 48.8 (CH), 47.8 (CH2), 32.4 
(CH2), 32.2 (CH2), 30.9 (CH2), 25.6 (CH2), 24.6 (CH2). HRMS (EI) m/z: calculated for C26H27ClN3O5 
[M+H+] 496.1634; found 496.1642.
General procedure for the synthesis of pyrrolobenzodiazepine-5-ones 12a-r. The 
corresponding pyrrolo derivative 6, 7 or 11 (1.0 mmol, 1.0 equiv., 0.1 M) was dissolved in 
ethanol (10 mL) and SnCl2·2H2O (10 mmol, 10 equiv.) and HCl 1 M (3.0 mmol, 3.0 equiv.) were 
succesively added to the solution. The mixture was stirred at 70 oC for one hour, after which 
the solvent was removed in a rotary evaporator. The raw product was dissolved in chloroform 
and washed with water (in each washing a saturated solution of Na2CO3 was added to the 
aqueous phase). The organic phase was dried over anhydrous sodium sulfate, filtered and 
concentrated to dryness, thus yielding the corresponding pyrrolobenzodiazepine-5-ones 12a-r.
N-Cyclohexyl-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12a). Light brown solid. Yield: 321 mg, 80%. M. p. 78-80 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.94 (d, J = 7.9 Hz, 1H), 7.57-7.40 (m, 6H), 7.32-7.24 (m, 2H), 
5.52 (d, J = 8.6 Hz, 1H, NH), 3.98-3.81 (m, 2H), 3.39-3.27 (m, 1H), 2.68 (dt, J = 12.4, 6.0 Hz, 1H), 
2.25 (ddd, J = 13.7, 8.8, 6.0 Hz, 1H), 1.76 (tt, J = 12.4, 6.0 Hz, 1H), 1.66-0.41 (m, 11H). 13C NMR 
{DEPT-135} (75 MHz, CDCl3) δ: 171.1 (Cq), 169.1 (Cq), 166.0 (Cq), 145.1 (Cq), 138.9 (Cq), 132.1 
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(CHAr), 129.6 (CHAr), 129.1 (CHAr), 128.2 (CHAr), 127.7 (CHAr), 127.3 (CHAr), 126.4 (CHAr), 125.0 
(Cq), 70.1 (Cq), 49.0 (CH2), 48.4 (CH), 40.2 (CH2), 32.5 (CH2), 32.2 (CH2), 25.2 (CH2), 24.9 (CH2), 
24.7 (CH2), 22.3 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H28N3O2 [M+H+] 402.2176; 
found 402.2179.
N-Cyclohexyl-5-oxo-11-(p-tolyl)-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12b). Light brown solid. Yield: 332 mg, 80%. M. p. 120-121 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.96 (dd, J = 7.8, 1.5 Hz, 1H), 7.52-7.44 (m, 3H), 7.35-7.23 (m, 
4H), 5.37 (d, J = 8.6 Hz, 1H, NH), 3.99-3.79 (m, 2H), 3.42-3.29 (m, 1H), 2.74 (dt, J = 12.8, 6.1 Hz, 
1H), 2.40 (s, 3H), 2.32-2.22 (m, 2H), 1.82-0.81 (m, 10H), 0.52-0.39 (m, 1H). 13C NMR {DEPT-135} 
(75 MHz, CDCl3) δ: 171.1 (Cq), 169.2 (Cq), 166.0 (Cq), 145.1 (Cq), 139.2 (Cq), 136.1 (Cq), 132.0 
(CHAr), 129.5 (CHAr), 128.8 (CHAr), 127.7 (CHAr), 127.3 (CHAr), 126.3 (CHAr), 125.0 (Cq), 70.1 (Cq), 
48.9 (CH2), 48.3 (CH), 40.3 (CH2), 32.5 (CH2), 32.2 (CH2), 25.2 (CH2), 24.9 (CH2), 24.7 (CH2), 22.3 
(CH2), 21.4 (CH3). HRMS (ESI-QTOF) m/z: calculated for C26H30N3O2 [M+H+] 416.2333; found 
416.2335.
11-(4-Chlorophenyl)-N-cyclohexyl-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12c). Light brown solid. Yield: 349 mg, 80%. M. p. 178-180 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.97-7.94 (m, 1H), 7.55-7.23 (m, 7H), 5.43 (d, J = 8.4 Hz, 1H, 
NH), 3.99-3.80 (m, 2H), 3.40-3.28 (m, 1H), 2.64 (dt, J = 13.1, 6.4 Hz, 1H), 2.28 (ddd, J = 13.9, 8.4, 
6.4 Hz, 1H), 1.84-1.73 (m, 2H), 1.64-0.31 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 
170.1 (Cq), 169.0 (Cq), 165.8 (Cq), 144.8 (Cq), 137.4 (Cq), 135.2 (Cq), 132.1 (CHAr), 129.5 (CHAr), 
129.2 (CHAr), 128.5 (CHAr), 127.3 (CHAr), 126.6 (CHAr), 124.9 (Cq), 70.0 (Cq), 49.0 (CH2), 48.4 
(CH), 40.3 (CH2), 32.5 (CH2), 32.2 (CH2), 25.1 (CH2), 24.9 (CH2), 24.6 (CH2), 22.3 (CH2). HRMS 
(ESI-QTOF) m/z: calculated for C25H27ClN3O2 [M+H+] 436.1786; found 436.1788.
N-(tert-Butyl)-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12d). Light brown solid. Yield: 353 mg, 94%. M. p. 105-106 
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oC. 1H NMR (300 MHz, CDCl3) δ: 7.99-7.96 (m, 1H), 7.58-7.25 (m, 8H), 5.44 (s, 1H, NH), 4.02-
3.93 (m, 1H), 3.87-3.77 (m, 1H), 2.72 (dt, J = 11.8, 5.8 Hz, 1H), 2.31-2.21 (m, 1H), 1.77 (tt, J = 
11.8, 5.8 Hz, 1H), 1.64-1.53 (m, 1H), 0.91 (s, 9H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 171.4 
(Cq), 169.2 (Cq), 166.2 (Cq), 145.2 (Cq), 138.8 (Cq), 132.0 (CHAr), 129.3 (CHAr), 129.1 (CHAr), 
128.2 (CHAr), 127.7 (CHAr), 127.4 (CHAr), 126.4 (CHAr), 125.3 (Cq), 70.6 (Cq), 51.4 (Cq), 48.9 (CH2), 
39.9 (CH2), 27.9 (CH3), 22.3 (CH2). HRMS (ESI-QTOF) m/z: calculated for C23H26N3O2 [M+H+] 
376.2020; found 376.2022.
N-Butyl-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-11a-
carboxamide (12e). Light brown solid. Yield: 357 mg, 95%. M. p. 149-150 oC. 1H NMR (300 MHz, 
CDCl3) δ: 7.92 (dd, J = 8.2, 1.2 Hz, 1H), 7.58-7.40 (m, 6H), 7.32 (dd, J = 8.2, 1.2 Hz, 1H), 7.28-
7.23 (m, 1H), 5.98 (t, J = 5.8 Hz, 1H, NH), 3.97-3.81 (m, 2H), 3.02-2.90 (m, 1H), 2.77-2.63 (m, 
2H), 2.26 (ddd, J = 13.5, 8.7, 6.5 Hz, 1H), 1.83-1.71 (m, 1H), 1.66-1.52 (m, 1H), 1.02-0.80 (m, 
4H), 0.71 (t, J = 6.9 Hz, 3H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 171.0 (Cq), 170.1 (Cq), 
165.9 (Cq), 145.0 (Cq), 139.0 (Cq), 132.0 (CHAr), 129.5 (CHAr), 129.1 (CHAr), 128.2 (CHAr), 127.7 
(CHAr), 127.4 (CHAr), 126.3 (CHAr), 124.9 (Cq), 70.1 (Cq), 49.0 (CH2), 40.2 (CH2), 39.4 (CH2), 31.3 
(CH2), 22.3 (CH2), 19.9 (CH2), 13.7 (CH3). HRMS (ESI-QTOF) m/z: calculated for C23H26N3O2 
[M+H+] 376.2020; found 376.2016.
7-Chloro-N-cyclohexyl-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12f). Light brown solid. Yield: 305 mg, 70%. M. p. 178-179 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.91 (d, J = 2.3 Hz, 1H), 7.54-7.40 (m, 6H), 7.25 (d, J = 8.6 Hz, 
1H), 5.63 (d, J = 8.6 Hz, 1H, NH), 3.96-3.80 (m, 2H), 3.44-3.32 (m, 1H), 2.69 (dt, J = 12.7, 6.4 Hz, 
1H), 2.26 (ddd, J = 14.1, 8.6, 6.4 Hz, 1H), 1.84-1.48 (m, 6H), 1.22-0.51 (m, 6H). 13C NMR {DEPT-
135} (75 MHz, CDCl3) δ: 171.6 (Cq), 168.9 (Cq), 164.7 (Cq), 143.6 (Cq), 138.7 (Cq), 132.1 (CHAr), 
129.3 (CHAr), 129.1 (CHAr), 129.0 (CHAr), 128.3 (CHAr), 127.6 (CHAr), 126.4 (Cq), 70.2 (Cq), 49.0 
(CH2), 48.5 (CH), 40.0 (CH2), 32.5 (CH2), 32.3 (CH2), 25.2 (CH2), 24.9 (CH2), 24.7 (CH2), 22.3 (CH2). 
HRMS (ESI-QTOF) m/z: calculated for C25H27ClN3O2 [M+H+] 436.1786; found 436.1783.
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a][1,4]diazepine-11a-carboxamide (12g). Light brown solid. Yield: 351 mg, 78%. M. p. 158-160 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.90 (d, J = 8.5 Hz, 1H), 7.44 (d, J = 8.2 Hz, 2H), 7.35 (d, J = 2.1 
Hz, 1H), 7.27-7.24 (m, 3H), 5.53 (d, J = 8.5 Hz, 1H, NH), 3.96-3.81 (m, 2H), 3.48-3.34 (m, 1H), 
2.76 (dt, J = 13.0, 6.0 Hz, 1H), 2.41 (s, 3H), 2.33-2.23 (m, 1H), 1.85-0.84 (m, 11H), 0.61-0.48 (m, 
1H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 172.7 (Cq), 168.9 (Cq), 165.4 (Cq), 146.1 (Cq), 
139.5 (Cq), 137.9 (Cq), 135.7 (Cq), 131.0 (CHAr), 128.9 (CHAr), 127.6 (CHAr), 127.1 (CHAr), 126.5 
(CHAr), 123.5 (Cq), 70.3 (Cq), 49.1 (CH2), 48.5 (CH), 40.1 (CH2), 32.5 (CH2), 32.3 (CH2), 25.2 (CH2), 
24.9 (CH2), 24.7 (CH2), 22.3 (CH2), 21.4 (CH3). HRMS (ESI-QTOF) m/z: calculated for 
C26H28ClNaN3O2 [M+Na+] 472.1762; found 472.1763.
N-(tert-Butyl)-8-chloro-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12h). Light brown solid. Yield: 311 mg, 76%. M. p. 215-216 
oC. 1H NMR (300 MHz, CDCl3) δ: 7.89 (d, J = 8.5 Hz, 1H), 7.52-7.23 (m, 7H), 5.30 (s, 1H, NH), 
3.95-3.75 (m, 2H), 2.69 (dt, J = 13.5, 5.7 Hz, 1H), 2.24 (ddd, J = 13.5, 9.1, 6.6 Hz, 1H), 1.81-1.69 
(m, 1H), 1.65-1.49 (m, 1H), 0.93 (s, 9H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 172.7 (Cq), 
168.9 (Cq), 165.1 (Cq), 146.1 (Cq), 138.4 (Cq), 137.8 (Cq), 130.9 (CHAr), 129.3 (CHAr), 128.2 
(CHAr), 127.6 (CHAr), 126.9 (CHAr), 126.6 (CHAr), 123.8 (Cq), 70.7 (Cq), 51.6 (Cq), 49.0 (CH2), 39.8 
(CH2), 27.9 (CH3), 22.3 (CH2). HRMS (ESI-QTOF) m/z: calculated for C23H25ClN3O2 [M+H+] 
410.1630; found 410.1629.
8-Chloro-N-cyclohexyl-11-(4-methoxyphenyl)-5-oxo-2,3,5,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepine-11a-carboxamide (12i). Light brown solid. Yield: 382 mg, 
82%. M. p. 114-115 oC. 1H NMR (300 MHz, CDCl3) δ: 7.90 (d, J = 8.5 Hz, 1H), 7.49 (d, J = 8.8 Hz, 
2H), 7.34 (d, J = 2.1 Hz, 1H), 7.25 (dd, J = 8.5, 2.1 Hz, 1H), 6.96 (d, J = 8.8 Hz, 2H), 5.32 (d, J = 8.2 
Hz, 1H, NH), 3.85 (s, 3H), 3.89-3.83 (m, 2H), 3.47-3.35 (m, 1H), 2.78 (dt, J = 13.5, 6.4 Hz, 1H), 
2.30 (ddd, J = 13.5, 8.3, 6.4 Hz, 1H), 1.86-1.48 (m, 6H), 1.27-0.47 (m, 6H). 13C NMR {DEPT-135} 
(75 MHz, CDCl3) δ: 171.8 (Cq), 168.8 (Cq), 165.3 (Cq), 160.5 (Cq), 146.1 (Cq), 137.8 (Cq), 131.1 
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(CHAr), 129.4 (CHAr), 127.0 (CHAr), 126.4 (CHAr), 123.4 (Cq), 113.6 (CHAr), 70.4 (Cq), 55.4 (CH3), 
49.1 (CH2), 48.5 (CH), 40.3 (CH2), 32.5 (CH2), 32.3 (CH2), 25.1 (CH2), 24.9 (CH2), 24.7 (CH2), 22.3 
(CH2). HRMS (ESI-QTOF) m/z: calculated for C26H29ClN3O3 [M+H+] 466.1892; found 466.1890.
N-Cyclohexyl-5-oxo-11-phenyl-5,11a-dihydro-3H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-11a-
carboxamide (12j). Brown solid. Yield: 379 mg, 95%. M. p. 70-72 oC. 1H NMR (300 MHz, CDCl3) 
δ: 7.96 (d, J = 7.9 Hz, 1H), 7.55-7.27 (m, 8H), 6.01 (d, J = 6.3 Hz, 1H), 5.86 (d, J = 6.3 Hz, 1H), 
5.44 (d, J = 8.5 Hz, 1H, NH), 4.73-4.51 (m, 2H), 3.36-3.23 (m, 1H), 1.58-0.37 (m, 10H). 13C NMR 
{DEPT-135} (75 MHz, CDCl3) δ: 169.4 (Cq), 166.8 (Cq), 165.4 (Cq), 145.2 (Cq), 139.2 (Cq), 132.2 
(CH), 130.5 (CH), 129.5 (CH), 129.2 (CH), 128.2 (CH), 127.8 (CH), 127.2 (CH), 127.0 (CH), 126.3 
(CH), 124.7 (Cq), 76.2 (Cq), 55.2 (CH2), 48.4 (CH), 32.3 (CH2), 32.2 (CH2), 25.1 (CH2), 24.8 (CH2), 
24.6 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H26N3O2 [M+H+] 400.2020; found 400.2024.
N-Cyclohexyl-5-oxo-11-(p-tolyl)-5,11a-dihydro-3H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-11a-
carboxamide (12k). Brown solid. Yield: 347 mg, 84%. M. p. 168-170 oC. 1H NMR (300 MHz, 
CDCl3) δ: 7.96 (dd, J = 8.0, 1.6 Hz, 1H), 7.50 (app. td, ddd, J = 8.0, 8.0, 1.6 Hz, 1H), 7.42-7.18 (m, 
6H), 6.00 (dt, J = 6.2, 2.0 Hz, 1H), 5.89 (dt, J = 6.2, 2.0 Hz, 1H), 5.42 (d, J = 8.5 Hz, 1H, NH), 4.65 
(dt, J = 17.5, 2.1 Hz, 1H), 4.56 (dt, J = 17.5, 2.1 Hz, 1H), 3.34-3.25 (m, 1H), 2.36 (s, 3H), 1.68-0.39 
(m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 169.7 (Cq), 166.9 (Cq), 165.4 (Cq), 145.3 (Cq), 
139.4 (Cq), 136.4 (Cq), 132.2 (CH), 130.6 (CH), 129.5 (CH), 128.8 (CH), 127.9 (CH), 127.2 (CH), 
126.9 (CH), 126.2 (CH), 124.7 (Cq), 76.2 (Cq), 55.2 (CH2), 48.4 (CH), 32.3 (CH2), 32.2 (CH2), 25.1 
(CH2), 24.8 (CH2), 24.6 (CH2), 21.4 (CH3). HRMS (ESI-QTOF) m/z: calculated for C26H28N3O2 
[M+H+] 414.2176; found 414.2181.
N-Cyclohexyl-11-(4-methoxyphenyl)-5-oxo-5,11a-dihydro-3H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12l). Brown solid. Yield: 292 mg, 68%. M. p. 178-180 oC. 1H 
NMR (300 MHz, CDCl3) δ: 7.95 (dd, J = 8.0, 1.4 Hz, 1H), 7.53-7.45 (m, 3H), 7.36 (dd, J = 8.0, 1.4 
Hz, 1H), 7.27 (app. td, ddd, J = 8.0, 8.0, 1.4 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 6.03 (dt, J = 6.5, 2.0 
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Hz, 1H), 5.93 (dt, J = 6.5, 2.0 Hz, 1H), 5.40 (d, J = 8.5 Hz, 1H, NH), 4.66 (dt, J = 17.5, 2.1 Hz, 1H), 
4.56 (dt, J = 17.5, 2.1 Hz, 1H), 3.81 (s, 3H), 3.33-3.23 (m, 1H), 1.55-0.36 (m, 10H). 13C NMR 
{DEPT-135} (75 MHz, CDCl3) δ: 168.7 (Cq), 166.8 (Cq), 165.4 (Cq), 160.5 (Cq), 145.3 (Cq), 132.2 
(CH), 131.7 (Cq), 130.6 (CH), 129.8 (CH), 129.5 (CH), 127.2 (CH), 126.9 (CH), 126.1 (CH), 124.6 
(Cq), 113.5 (CH), 76.4 (Cq), 55.3 (CH3), 55.2 (CH2), 48.4 (CH), 32.3 (CH2), 32.2 (CH2), 25.1 (CH2), 
24.8 (CH2), 24.6 (CH2). HRMS (ESI-QTOF) m/z: calculated for C26H28N3O3 [M+H+] 430.2125; 
found 430.2132.
N-(tert-Butyl)-5-oxo-11-phenyl-5,11a-dihydro-3H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-11a-
carboxamide (12m). Brown solid. Yield: 280 mg, 75%. M. p. 144-146 oC. 1H NMR (300 MHz, 
CDCl3) δ: 7.99-7.96 (m, 1H), 7.54-7.27 (m, 8H), 6.01 (dt, J = 6.3, 1.8 Hz, 1H), 5.85 (dt, J = 6.3, 1.8 
Hz, 1H), 5.22 (s, 1H, NH), 4.69-4.53 (m, 2H), 0.87 (s, 9H). 13C NMR {DEPT-135} (75 MHz, CDCl3) 
δ: 169.7 (Cq), 166.8 (Cq), 165.4 (Cq), 145.2 (Cq), 139.2 (Cq), 132.1 (CH), 130.5 (CH), 129.3 (CH), 
129.2 (CH), 128.1 (CH), 127.8 (CH), 127.3 (CH), 127.0 (CH), 126.3 (CH), 124.9 (Cq), 76.4 (Cq), 
55.2 (CH2), 51.5 (Cq), 27.9 (CH3). HRMS (ESI-QTOF) m/z: calculated for C23H24N3O2 [M+H+] 
374.1863; found 374.1865.
7-Chloro-N-cyclohexyl-5-oxo-11-phenyl-5,11a-dihydro-3H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12n). Brown solid. Yield: 282 mg, 65%. M. p. 178-180 oC. 
1H NMR (300 MHz, CDCl3) δ: 7.93 (d, J = 2.5 Hz, 1H), 7.50-7.37 (m, 6H), 7.31 (d, J = 8.6 Hz, 1H), 
6.01 (dt, J = 6.3, 2.1 Hz, 1H), 5.85 (dt, J = 6.3, 2.1 Hz, 1H), 5.56 (d, J = 8.5 Hz, 1H, NH), 4.66 (dt, J 
= 17.5, 2.2 Hz, 1H), 4.55 (dt, J = 17.5, 2.2 Hz, 1H), 3.41-3.27 (m, 1H), 1.59-0.47 (m, 10H). 13C 
NMR {DEPT-135} (75 MHz, CDCl3) δ: 169.9 (Cq), 166.5 (Cq), 164.1 (Cq), 143.8 (Cq), 138.9 (Cq), 
132.2 (CH), 131.9 (Cq), 130.3 (CH), 129.4 (CH), 129.1 (CH), 128.9 (CH), 128.2 (CH), 127.8 (CH), 
127.1 (CH), 126.1 (Cq), 76.2 (Cq), 55.3 (CH2), 48.6 (CH), 32.3 (CH2), 32.2 (CH2), 25.1 (CH2), 24.8 
(CH2), 24.7 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H25ClN3O2 [M+H+] 434.1630; found 
434.1634.
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a][1,4]diazepine-11a-carboxamide (12o). Yellow solid. Yield: 304 mg, 70%. M. p. 78-80 oC. 1H 
NMR (300 MHz, CDCl3) δ: 7.89 (d, J = 8.5 Hz, 1H), 7.50-7.37 (m, 6H), 7.24 (dd, J = 8.5, 2.1 Hz, 
1H), 6.00 (d, J = 6.3, 2.3 Hz, 1H), 5.84 (d, J = 6.3, 2.3 Hz, 1H), 5.49 (d, J = 8.5 Hz, 2H, NH), 4.64 
(dt, J = 17.5, 2.2 Hz, 1H), 4.53 (dt, J = 17.5, 2.2 Hz, 1H), 3.39-3.25 (m, 1H), 1.55-0.43 (m, 10H). 
13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 170.4 (Cq), 166.5 (Cq), 164.5 (Cq), 146.1 (Cq), 138.8 
(Cq), 138.0 (Cq), 131.0 (CH), 130.2 (CH), 129.5 (CH), 128.2 (CH), 127.8 (CH), 127.2 (CH), 127.0 
(CH), 126.5 (CH), 123.2 (Cq), 76.3 (Cq), 55.3 (CH2), 48.6 (CH), 32.3 (CH2), 25.1 (CH2), 24.8 (CH2), 
24.6 (CH2). HRMS (ESI-QTOF) m/z: calculated for C25H25ClN3O2 [M+H+] 434.1630; found 
434.1634.
N-Cyclohexyl-1-methylene-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12p). Brown solid. Yield: 248 mg, 60%. M. p. 154-156 oC. 
1H NMR (300 MHz, CDCl3) δ: 7.96 (d, J = 7.9 Hz, 1H), 7.54-7.26 (m, 8H), 5.49 (d, J = 8.2 Hz, 1H, 
NH), 5.32 (s, 1H), 5.17 (s, 1H), 4.15 (t, J = 10.7 Hz, 1H), 3.81-3.71 (m, 1H), 3.32-3.22 (m, 1H), 
2.51 (dd, J = 15.6, 7.3 Hz, 1H), 2.32-2.20 (m, 1H), 1.55-0.50 (m, 10H). 13C NMR {DEPT-135} (75 
MHz, CDCl3) δ: 169.4 (Cq), 166.3 (Cq), 166.2 (Cq), 146.5 (Cq), 145.3 (Cq), 137.8 (Cq), 132.3 
(CHAr), 129.7 (CHAr), 129.2 (CHAr), 128.4 (CHAr), 127.6 (CHAr), 127.1 (CHAr), 126.3 (CHAr), 125.1 
(Cq), 114.8 (CH2), 73.1 (Cq), 48.5 (CH), 46.9 (CH2), 32.2 (CH2), 32.1 (CH2), 30.6 (CH2), 25.2 (CH2), 
24.8 (CH2), 24.7 (CH2). HRMS (ESI-QTOF) m/z: calculated for C26H28N3O2 [M+H+] 414.2176; 
found 414.2182.
N-(tert-Butyl)-1-methylene-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-
a][1,4]diazepine-11a-carboxamide (12q). White solid. Yield: 225 mg, 58%. M. p. 102-104 oC. 1H 
NMR (300 MHz, CDCl3) δ: 7.96 (dd, J = 7.9, 1.7 Hz, 1H), 7.52-7.20 (m, 8H), 5.34 (d, J = 1.7 Hz, 
1H, NH), 5.16-5.14 (m, 2H), 4.13 (ddd, J = 11.9, 10.0, 2.5 Hz, 1H), 3.65 (ddd, J = 11.9, 10.0, 7.6 
Hz, 1H), 2.53-2.45 (m, 1H), 2.30-2.17 (m, 1H), 0.87 (s, 9H). 13C NMR {DEPT-135} (75 MHz, CDCl3) 
δ: 166.5 (Cq), 166.0 (Cq), 146.7 (Cq), 145.5 (Cq), 138.1 (Cq), 132.1 (CHAr), 129.4 (CHAr), 129.0 
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(CHAr), 128.3 (CHAr), 127.5 (CHAr), 127.2 (CHAr), 126.2 (CHAr), 125.5 (Cq), 114.1 (CH2), 73.3 (Cq), 
51.2 (Cq), 46.4 (CH2), 30.6 (CH2), 27.7 (CH3). HRMS (ESI-QTOF) m/z: calculated for C24H26N3O2 
[M+H+] 388.2020; found 388.2031.
8-Chloro-N-cyclohexyl-1-methylene-5-oxo-11-phenyl-2,3,5,11a-tetrahydro-1H-
benzo[e]pyrrolo[1,2-a][1,4]diazepine-11a-carboxamide (12r). Brown solid. Yield: 278 mg, 
62%. M. p. 118-120 oC. 1H NMR (300 MHz, CDCl3) δ: 7.90 (d, J = 8.5 Hz, 1H), 7.46-7.23 (m, 7H), 
5.37 (d, J = 8.4 Hz, 1H, NH), 5.31 (d, J = 2.3 Hz, 1H), 5.19 (d, J = 2.3 Hz, 1H), 4.11 (ddd, J = 11.9, 
9.3, 2.5 Hz, 1H), 3.72 (ddd, J = 11.9, 9.3, 7.7 Hz, 1H), 3.40-3.27 (m, 1H), 2.52 (ddd, J = 15.5, 7.7, 
2.5 Hz, 1H), 2.32-2.19 (m, 1H), 1.67-0.53 (m, 10H). 13C NMR {DEPT-135} (75 MHz, CDCl3) δ: 
170.2 (Cq), 166.2 (Cq), 165.3 (Cq), 146.4 (Cq), 138.1 (Cq), 137.7 (Cq), 131.1 (CH), 129.3 (CH), 
128.3 (CH), 127.6 (CH), 127.0 (CH), 126.4 (CH), 123.7 (Cq), 114.6 (CH2), 73.2 (Cq), 48.5 (CH), 
46.8 (CH2), 32.3 (CH2), 32.2 (CH2), 30.6 (CH2), 25.2 (CH2), 24.8 (CH2), 24.7 (CH2). HRMS (EI) m/z: 
calculated for C26H27ClN3O2 [M+H+] 448.1786; found 448.1793.
Associated content
The Supporting Information is available free of charge on the ACS Publications website at DOI: 
xx.xxxx/acs.joc.xxxxxxx.
Copies of 1H, 13C and DEPT-135 NMR spectra and high-resolution mass spectra (PDF).
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